Table 1.
Binding activities of RNA aptamers in yeast and in vitro
| Aptamera | Proteinb | β-Galactosidasec (MS2 cassette) | β-Galactosidasec (T-cassette) | Kd, nMd |
|---|---|---|---|---|
| – | AD | 0.3 ± 0.3 | 1.0 ± 0.6 | – |
| R1 | AD | 2.2 ± 0.3 | 3.3 ± 2.3 | – |
| R1 | AD-mp502 | 1.7 ± 0.1 | 4.8 ± 3.3 | – |
| R1 | AD-mp652 | 100 | 476 ± 56 | 38 ± 20 |
| R1 | AD-hp652 | 4.4 ± 0.4 | – | – |
| R1 | AD-zp652 | 4.5 ± 0.3 | – | – |
| R1 | AD-dorsal2 | 1.7 ± 0.1 | 4.8 ± 3.3 | – |
| R1 | AD-dif2 | 2.1 ± 0.1 | 5.2 ± 3.3 | – |
| anti-p50 | AD | 1.9 ± 0.1 | 8.5 ± 0.5 | – |
| anti-p50 | AD-mp502 | 254 ± 14 | 576 ± 30 | – |
| anti-p50 | AD-mp652 | 2.5 ± 0.6 | 7.1 ± 1.0 | – |
| anti-p50 | AD-dorsal2 | 1.1 ± 0.1 | 5.2 ± 0.5 | – |
| anti-p50 | AD-dif2 | 0.9 ± 0.1 | 2.4 ± 0.5 | – |
| Y1 | AD | 1.5 ± 0.8 | – | – |
| Y1 | AD-mp652 | 375 ± 8 | 556 ± 90 | 74 ± 2 |
| Y1 | AD-hp652 | 38 ± 9 | – | – |
| Y1 | AD-zp652 | 175 ± 8 | – | – |
| Y1-1 | AD-mp65 | 113 ± 16 | 552 ± 90 | 86 ± 10 |
| Y1-1T | AD-mp652 | 161 ± 26 | – | 101 ± 50 |
| Y3 | AD | 1.1 ± 0.7 | – | – |
| Y3 | AD-mp652 | 73 ± 10 | 456 ± 142 | 94 ± 31 |
| Y3 | AD-hp652 | 8.3 ± 2.6 | – | – |
| Y3 | AD-zp652 | 80 ± 30 | – | – |
| Y3-1 | AD-mp652 | 86 ± 33 | 618 ± 123 | >2500 |
| Y3-1T | AD-mp652 | 90 ± 25 | – | >2500 |
Dash indicates not tested.
aRNA aptamers cloned in MS2 cassette, T-cassette, or tested in isolation in vitro. R1: 83 nt; anti-p50: 31 nt; Y1: 86 nt; Y1-1: 40 nt; Y1-1T: 39 nt; Y3: 83 nt; Y3-1: 32 nt; Y3-1T: 33 nt.
bAD: GAL4 activation domain.
cβ-galactosidase activities normalized to positive control combination MS2-R1-mp652 set at 100. Averages represent at least three independent trials for each transformant.
dEquilibrium dissociation constant from electrophoretic gel mobility shift data fit to Equation (1) for target protein without activation domain. Mean and standard deviation are shown based on at least two repeats.